Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case

Introduction: Cemiplimab, a monoclonal antibody directed against the PD-1 receptor of immune cells, has recent indication for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC).Case description: We present the clinical case of an elderly woman affected by locally advanced squamous carcinoma of the left cheek, in excellent response after only one course of therapy with cemiplimab, with good tolerability.Conclusions: Immunotherapy is a new therapeutic option in cSCC.

Automated summary

This case report presents an elderly woman with locally advanced squamous carcinoma who showed significant response and good tolerability after receiving Cemiplimab therapy. It demonstrates that immunotherapy is a new treatment option for cSCC.